© 2020 MJH Life Sciences and Urology Times. All rights reserved.
July 10, 2020
Steven A. Kaplan, MD, explains the updates in the AUA 2020 guideline on lower urinary tract symptoms secondary to benign prostatic hyperplasia.
July 09, 2020
At 10 years, the risk of distant metastasis was 0.6%.
July 08, 2020
Cabozantinib's single-agent activity opens the potential for combination approaches with immunotherapy in patients with heavily pretreated urothelial carcinoma.
Abnormalities in the androgen receptor gene detected in men with advanced prostate cancer were associated with poor responses to available drug treatments and reduced survival.